• In combination.
The Omni device from
Sight Science lets sur-
geons perform canalo-
plasty and trabeculo-
tomy at the same time
through a single inci-
sion. "You can remove
the trabecular mesh-
work, the greatest
resistance to fluid outflow, and also viscodilate Schlemm's canal,
allowing for the opening of collapsed fluid collector channels,"
explains Dr. Sarkisian.
There's no consensus on which method or device is best, according
to Dr. Sarkisian. "All appropriate modalities need to be included in the
patient care discussion," he adds.
What is widely accepted is that these methods are safe and effective
ways to reduce intraocular pressure and get patients off of burden-
some topical glaucoma therapies. Dr. Sarkisian also points out that
demand for the procedures will increase as the patient population
ages and patients become more aware of the many minimally invasive
glaucoma treatment options.
"Case volumes will continue to grow," says Dr. Sarkisian. "It's an
exciting time to be a glaucoma specialist. More importantly, it's a
much better time to be a patient."
OSM
D E C E M B E R 2 0 1 8 • O U T PA T I E N T S U R G E R Y. N E T • 5 7
• LESS PHACO The miLoop is best suited for halving dense cataracts in order to
lessen the amount of phaco energy needed to fragment the lenses.
